This study tests a new drug called onvansertib added to standard chemotherapy and a targeted therapy for people with advanced colorectal cancer that has a specific gene change (KRAS or NRAS mutation). About 113 people who have not had prior treatment for their metastatic cancer w…
Phase: PHASE2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated May 17, 2026 05:34 UTC